Diagnostics & Testing

Source BioScience provides laboratory services in genomics, multi-omics, histopathology, digital pathology, molecular diagnostics, and proteomics for pharmaceutical R&D and clinical applications. The company supports drug discovery, development research, clinical trials, and precision medicine with advanced sequencing, biomarker validation, and AI-assisted analysis. It offers accredited facilities compliant with ICH guidelines, GLP, and Human Tissue Authority licensing, enabling end-to-end solutions from research to diagnostics.

Primerdesign specializes in real-time qPCR assays, kits, and custom development services for molecular diagnostics in life sciences and pharma. They offer ready-to-deploy, open-platform assays for pathogen detection, surveillance, and genetic testing across food safety, animal health, and human diagnostics. With over 20 years of experience, their products support scalable workflows from research to outbreak response.

LifeArc provides intellectual property management, technology development, early-stage drug discovery, antibody humanization, and diagnostics development services to academic, biotech, and pharmaceutical organizations. It offers funding, partnerships, and commercialization support to translate research into therapies, with successes including pembrolizumab and lecanemab. Profits are reinvested into further medical research focused on rare diseases and global health challenges.

Luminex provides xMAP technology, a multiplexed assay platform that enables simultaneous analysis of up to 500 analytes like cytokines, chemokines, and growth factors from minimal sample volumes. It combines proprietary microspheres, advanced fluidics, optics, and digital signal processing for high-throughput quantification in a single reaction. The technology supports applications in biomarker discovery, preclinical studies, inflammation, cancer, and metabolic disease research.

MGI Tech is a leading Chinese biotechnology company specializing in high-throughput DNA sequencers, multi-omics platforms, and lab automation systems for life sciences and healthcare. The company manufactures clinical-grade gene sequencers using DNA nanoball sequencing technology, offering solutions for genomic research, precision medicine, and genetic testing with industry-leading throughput and cost-effectiveness. MGI serves over 3,560 users across 5,300 installations globally, providing comprehensive workflows from sample preparation through bioinformatics analysis.

MOBILion Systems offers high-resolution ion mobility mass spectrometry (HRIM-MS) instruments based on proprietary SLIM technology for proteomics, metabolomics, lipidomics, and biomarker discovery in pharma and biopharma. Their MOBIE platform provides superior separation of complex biomolecules with resolving power over 250, enabling deeper proteome coverage, confident identification of low-abundance species and post-translational modifications at higher throughput. This addresses tradeoffs in sensitivity, specificity, and speed in conventional LC-MS workflows, supporting drug development and diagnostics.

Tagomics is a biomarker discovery and diagnostics company offering a proprietary multiomics platform that integrates genomics, epigenomics, and fragmentomics to unlock disease-associated biomarkers from biological sources. The company's Interlace platform combines novel epigenomic profiling with advanced machine learning to provide comprehensive disease insights, with a focus on early cancer detection through blood-based liquid biopsy tests.

Oxford Nanopore Technologies offers nanopore-based DNA/RNA sequencing platforms, including portable devices like MinION and high-throughput systems like PromethION, for life sciences and pharmaceutical R&D. These enable rapid, real-time molecular analysis with easy library preparation and compatibility with third-party products from partners such as 10x Genomics, Thermo Fisher Scientific, and Agilent. Distribution is supported globally through agreements like with Avantor for MinION devices in the US and Europe.

Olink, part of Thermo Fisher Scientific, offers multiplexed proteomics panels measuring up to 5,400 proteins with high specificity for biomarker discovery and analysis in life sciences and pharma research. They provide Olink Analysis Services through certified labs in Uppsala and Boston, handling pre-study consultation to data delivery, or kits for in-house use. A global network of certified service providers, including CROs, enables scalable, high-throughput protein profiling with low sample volumes.

Olink provides multiplexed proteomics solutions using Proximity Extension Assay (PEA) technology for high-throughput analysis of up to 5,400 proteins with high specificity and sensitivity. They offer targeted and explore panels focused on areas like inflammation, oncology, cardiometabolic, and neurology, available as kits for labs or through certified analysis services. These tools support biomarker discovery and research in pharma and life sciences with small sample volumes and scalable quantification.

OncoHost provides PROphet®, an AI-powered precision oncology platform that analyzes proteomic patterns from a single pre-treatment blood sample to predict clinical benefit, resistance mechanisms, and toxicities in cancer patients. The tool supports clinical decision-making for immunotherapy and combination therapies, particularly in NSCLC, by combining systems biology, bioinformatics, and machine learning. It enables personalized treatment plans to improve patient outcomes and reduce unnecessary therapies.

Oxford Nanopore Technologies develops and sells nanopore sequencing products including the portable MinION, desktop GridION, and high-throughput PromethION for direct electronic analysis of DNA, RNA, proteins, and small molecules. These devices enable real-time, long-read sequencing applicable to pharmaceutical R&D in personalized medicine, cancer research, immune system analysis, and clinical diagnostics. The technology supports genome assembly, structural variation detection, and antibody therapy development with scalable, field-deployable solutions.

PacBio provides highly accurate long-read sequencing technology (HiFi reads with 99.9% accuracy) for genome, transcriptome, and epigenome analysis. The platform enables de novo genome assemblies, structural variant detection, and full-length transcript sequencing without assembly. PacBio serves pharmaceutical R&D applications including plasmid sequencing, cell line verification, mRNA polyA tail measurement, and directed evolution studies.

Parse Biosciences provides scalable single cell sequencing solutions using Evercode combinatorial barcoding technology, enabling analysis of up to 1 million cells from 384 samples in a single run without specialized instruments. Their portfolio includes Evercode Whole Transcriptome, TCR, BCR, Gene Select, and CRISPR Detect kits, supporting applications in immunology, drug discovery, and multi-omics research. The GigaLab service scales to billions of cells annually for large-scale projects.

PBD Biotech develops Actiphage®, a patented phage-based diagnostic technology that detects live mycobacteria, the cause of tuberculosis, in blood samples and other specimens within 8 hours. The test distinguishes viable from non-viable organisms, enabling differentiation between active infections and vaccination responses. Recent innovations include a lyophilized PCR reaction bead for ambient shipping of active TB tests.

PerkinElmer provides end-to-end solutions in detection, imaging, informatics, and services for life sciences and diagnostics, enabling personalized therapies and faster diagnoses. They offer analytical instruments, consumables, and software for research, development, environmental analysis, and lab optimization in pharma and biotech. With nearly 90 years of experience, their global team supports sustainable scientific discovery and regulatory compliance.

Personalis provides advanced genomic sequencing and analysis services for precision oncology, including the ACE Technology platform to interrogate difficult genome regions and ImmunoID NeXT for multidimensional tumor profiling. They offer NeXT Personal, an ultra-sensitive liquid biopsy assay for minimal residual disease (MRD) detection using whole genome sequencing on FFPE tissue. Personalis operates an on-site CAP-accredited clinical lab to support biopharma in developing next-generation cancer therapies and diagnostics.

PlaqueTec is a precision medicine company pioneering biomarker-based strategies for coronary artery disease (CAD), the leading cause of death worldwide. The company has developed the Liquid Biopsy System (LBS), a specialized catheter that collects blood samples containing biomolecules from coronary plaque at multiple sites simultaneously. PlaqueTec collaborates with research institutions and drug discovery partners to identify endotype-specific biomarkers and advance personalized treatment approaches for CAD.

Plasmidsaurus provides ultrafast whole plasmid sequencing using nanopore technology for full sequence verification and error detection. They offer RNA-Seq services for genome-wide gene expression analysis from crude cell preps, with turnaround times of 3 days in the US or one week globally. Additional services include amplicons, whole genomes, AAV, and microbiomes, serving pharmaceutical companies, biotech startups, and research labs.

Alamar Biosciences is a proteomics company providing ultra-sensitive protein biomarker detection platforms for early disease detection and precision health research. The company's NULISA technology and ARGO HT system enable attomolar-level sensitivity with up to 12-log dynamic range for multiplexed protein analysis from liquid biopsies. Their applications span early-stage discovery, translational research, and clinical diagnostics, with particular focus on neurological and inflammatory biomarker detection.

Primerdesign is a leader in real-time qPCR solutions, offering precision-designed primers, probes, and assays for life sciences and pharmaceutical applications. Their products support gene expression analysis, pathogen detection, and diagnostics, ensuring high specificity and reliability in R&D workflows. They provide ready-to-use kits and custom solutions optimized for quantitative PCR.

ProteomEdge develops multiplex panels of isotope-labeled protein standards for absolute protein quantification using mass spectrometry. Their products support biomarker research and translational applications in blood-based proteomics for pharma and life sciences. The company offers DiscoveryEdge 600 and plans additional targeted panels and expanded discovery products in early 2026.

Biognosys provides next-generation proteomics solutions for pharmaceutical R&D and life sciences organizations, specializing in mass spectrometry-based protein analysis, proteogenomics, and biomarker discovery. Their platform enables comprehensive protein expression profiling, post-translational modification analysis, and quantitative proteome characterization to support drug development, target validation, and personalized medicine applications.

ProtonDx develops portable point-of-care molecular diagnostic platforms like Dragonfly for rapid detection of viral and bacterial pathogens in human and animal health, delivering PCR-quality results in under 30 minutes without lab infrastructure. Their Research Use Only (RUO) products support customizable testing for diseases including COVID-19, malaria, mpox, influenza, and veterinary pathogens like APP and GPS. Solutions include isothermal amplification, nucleic acid extraction kits, and multiplex assays adaptable for life sciences research, agriculture, and global health applications.